Post-vaccination Immune Response Research Articles

Postvaccinal immune response to regimens of Newcastle disease vaccination by filter paper sampling technique.

Seven hundred and ten blood samples were collected at random from commercial layers in Tamil Nadu on Whatman filter paper No. 1 instead of the conventional method of serum collection. The birds were subjected to different Newcastle disease (ND) vaccination schedules and samples were collected to study the vaccinal response to ND at field level. Eluates were obtained from sample areas of filter paper using Brij-35 solution [detergent] and subjected to the micro haemagglutination inhibition (HI) test for ND antibodies. The HI titre ranged from less than 2(4) to 2(9). The possible causes of poor immune response to ND vaccinations are discussed.

BCG vaccination in low birth weight newborns: Analysis of lymphocyte proliferation, IL-2 generation and intradermal reaction to PPD

Objective: To study vaccinal scar formation and post-vaccinal immune response in newborns with birth weight ranging from 2000 to 2499 g vaccinated in the first week of life with intradermal bacille Calmette-Guérin (BCG) (Moreau-Rio de Janeiro strain). Method: Specific immune response to PPD was assessed in 30 low birth weight newborns (mean birth weight = 2311.7 ± 122.1 g; mean gestational age = 38.1 ± 1.8 weeks) in comparison to 56 control infants (mean birth weight = 3198.9 ± 267.2 g; mean gestational age = 38.5 ± 1.2 weeks). Results: Low birth weight infants have an efficient immune response to vaccinal stimulus when compared to control infants as judged by specific in vitro lymphocyte proliferation (mean SI = 9.7 ± 12.9 vs SI = 8.8 ± 10.0, P = 0.72) and IL-2 production (mean SI = 3.1 ± 3.4 vs SI = 2.6 ± 2.0, P = 0.38). Intradermal reaction to PPD was also comparable in both groups (mean induration diameter = 9.5 ± 5.1 mm vs 9.6 ± 5.0 mm, P = 0.94). Conclusion: These data suggest that low birth weight newborns show a good immune response to BCG, thus reinforcing the inclusion of such infants in regular vaccination programs with intradermal BCG.